Skip to content

Lobbying by Eurofins CDMO Alphora Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Eurofins CDMO Alphora Inc.

Meetings this Parliament
8
With MPs
6
Since Nov 2021
8
Active registrations
1

Most recent reported meeting: Sep 9, 2026.

Who they meet

Since the current Parliament opened.

MPs

Institutions

  • House of Commons6
  • Innovation, Science and Economic Development Canada (ISED)2
  • Privy Council Office (PCO)1

Registrations in effect

In-house (corporation) In effect since Oct 16, 2026 Receives government funding

Filed by Geoff Evans, President

Lobbyists

  • Geoff Evans · President

Institutions they may lobby: House of Commons, Innovation, Science and Economic Development Canada (ISED), Invest in Canada Hub, Privy Council Office (PCO)

What they're lobbying on (2)
  • 232 tariffs. As of Sept. 30th, tariffs apply to Canada for commercial drug shipments to the US. The companies' goal is to ensure this issue is on the radar of our Federal government administrations (e.g. ISED) and politicians: contact their offices (calls, emails, in person) to make them aware of the risk to the Canadian CDMO industry. The goal is for this issue to be on the agenda if and when negitiations resume for reduction to a level competitive with other juridictions.
  • SRF application. The company presently has an application with the Strategic Response Fund for funding considering for an expansion at our Mississauga Ontario site. While it is at an advanced stage and near a decision, I may have contact with politicians and applicable personnel where it is raised and requires my declaration herein. Topics of discussion would be on status and timing for approval and public notification of approval. Such contact will be in person, though calls or emails..

Registration 966343-387708-3. Look it up in the official Registry

Reported meetings

Spreadsheet

  • Reported by Geoff Evans · In-house (corporation)

    • Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
    SRF application. The company presently has an application with the Strategic Response Fund for funding considering for an expansion at our Mississauga Ontario site. While it is at an advanced stage and near a decision, I may have contact with politicians and applicable personnel where it is raised and requires my declaration herein. Topics of discussion would be on status and timing for approval and public notification of approval. Such contact will be in person, though calls or emails.. Read more

    Official report

  • Reported by Geoff Evans · In-house (corporation)

    • Charles Sousa · Member of Parliament
    • Iqra Khalid · Federal MP
    • Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
    232 tariffs. As of Sept. 30th, 100% tariffs apply to Canada for commercial drug shipments to the US. The companies' goal is to ensure this issue is on the radar of our Federal government administrations (e.g. ISED) and politicians. I plan to contact their offices (calls, emails, in person where possible) to make them aware of the risk to the Canadian CDMO industry, manufacturing jobs, and to Canada's Life Science commercialization strategy. My goal is for this issue to be on the agenda to address by our trade negotiators if and when trade negitiations resume so they can be reduced to something reasonable (e.g. Europe is 15% whereas Canada is 100%). Read more

    Official report

  • Reported by Geoff Evans · In-house (corporation)

    • Dominic LeBlanc · President of the King’s Privy Council for Can. & Minister resp. for Can.–U.S. Trade, Intergov. Affairs, Int. Trade & One Can. Economy, Privy Council Office (PCO)
    232 tariffs. As of Sept. 30th, 100% tariffs apply to Canada for commercial drug shipments to the US. The companies' goal is to ensure this issue is on the radar of our Federal government administrations (e.g. ISED) and politicians. I plan to contact their offices (calls, emails, in person where possible) to make them aware of the risk to the Canadian CDMO industry, manufacturing jobs, and to Canada's Life Science commercialization strategy. My goal is for this issue to be on the agenda to address by our trade negotiators if and when trade negitiations resume so they can be reduced to something reasonable (e.g. Europe is 15% whereas Canada is 100%). Read more

    Official report

  • Reported by Geoff Evans · In-house (corporation)

    • Simone Racanelli · Office of the Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, House of Commons
    232 tariffs. As of Sept. 30th, 100% tariffs apply to Canada for commercial drug shipments to the US. The companies' goal is to ensure this issue is on the radar of our Federal government administrations (e.g. ISED) and politicians. I plan to contact their offices (calls, emails, in person where possible) to make them aware of the risk to the Canadian CDMO industry, manufacturing jobs, and to Canada's Life Science commercialization strategy. My goal is for this issue to be on the agenda to address by our trade negotiators if and when trade negitiations resume so they can be reduced to something reasonable (e.g. Europe is 15% whereas Canada is 100%). Read more

    Official report

  • Reported by Geoff Evans · In-house (corporation)

    • Simone Racanelli · Office of the Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, House of Commons
    232 tariffs. As of Sept. 30th, 100% tariffs apply to Canada for commercial drug shipments to the US. The companies' goal is to ensure this issue is on the radar of our Federal government administrations (e.g. ISED) and politicians. I plan to contact their offices (calls, emails, in person where possible) to make them aware of the risk to the Canadian CDMO industry, manufacturing jobs, and to Canada's Life Science commercialization strategy. My goal is for this issue to be on the agenda to address by our trade negotiators if and when trade negitiations resume so they can be reduced to something reasonable (e.g. Europe is 15% whereas Canada is 100%). Read more

    Official report

  • Reported by Geoff Evans · In-house (corporation)

    232 tariffs. As of Sept. 30th, 100% tariffs apply to Canada for commercial drug shipments to the US. The companies' goal is to ensure this issue is on the radar of our Federal government administrations (e.g. ISED) and politicians. I plan to contact their offices (calls, emails, in person where possible) to make them aware of the risk to the Canadian CDMO industry, manufacturing jobs, and to Canada's Life Science commercialization strategy. My goal is for this issue to be on the agenda to address by our trade negotiators if and when trade negitiations resume so they can be reduced to something reasonable (e.g. Europe is 15% whereas Canada is 100%). Read more

    Official report

  • Reported by Geoff Evans · In-house (corporation)

    SRF application. The company presently has an application with the Strategic Response Fund for funding considering for an expansion at our Mississauga Ontario site. While it is at an advanced stage and near a decision, I may have contact with politicians and applicable personnel where it is raised and requires my declaration herein. Topics of discussion would be on status and timing for approval and public notification of approval. Such contact will be in person, though calls or emails.. Read more

    232 tariffs. As of Sept. 30th, 100% tariffs apply to Canada for commercial drug shipments to the US. The companies' goal is to ensure this issue is on the radar of our Federal government administrations (e.g. ISED) and politicians. I plan to contact their offices (calls, emails, in person where possible) to make them aware of the risk to the Canadian CDMO industry, manufacturing jobs, and to Canada's Life Science commercialization strategy. My goal is for this issue to be on the agenda to address by our trade negotiators if and when trade negitiations resume so they can be reduced to something reasonable (e.g. Europe is 15% whereas Canada is 100%).

    Official report

  • Reported by Geoff Evans · In-house (corporation)

    232 tariffs. As of Sept. 30th, 100% tariffs apply to Canada for commercial drug shipments to the US. The companies' goal is to ensure this issue is on the radar of our Federal government administrations (e.g. ISED) and politicians. I plan to contact their offices (calls, emails, in person where possible) to make them aware of the risk to the Canadian CDMO industry, manufacturing jobs, and to Canada's Life Science commercialization strategy. My goal is for this issue to be on the agenda to address by our trade negotiators if and when trade negitiations resume so they can be reduced to something reasonable (e.g. Europe is 15% whereas Canada is 100%). Read more

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.